Jeanine Jarnes, PharmD, BCOP, BCPS

Assistant Professor, Department of Pediatrics
Jeanine Jarnes



Assistant Professor, Department of Pediatrics
Faculty Member, Division of Genetics and Metabolism
Adjunct Assistant Professor, Department of Experimental and Clinical Pharmacology (ECP)


PharmD, University of Minnesota College of Pharmacy, Minneapolis, MN


Fellowship in the Lysosomal Disease Network, University of Minnesota, Minneapolis, MN

Licensures and Certifications

Certificate Program in Genetics and Genomics, Stanford University, Palo Alto, CA
Certification in Pharmaceutical Care Practitioner, University of Minnesota College of Pharmacy
Board of Pharmacy Specialties- Pharmacotherapy
Board of Pharmacy Specialties- Oncology Pharmacy
Board Certified Registered Pharmacist, State of Minnesota

Expand all


Jeanine Jarnes, PharmD, is an Assistant Professor in the University of Minnesota Department of Pediatrics and is an adjunct assistant professor in the College of Pharmacy, University of Minnesota. Jeanine is a board certified Pharmacotherapy Specialist, as well as having a board certification in oncology pharmacy. Jeanine works as a pharmacotherapy provider for patients with inherited metabolic diseases at the University of Minnesota Specialty Clinics. She also serves as a Clinical Pharamcogeneticist for the Lysosomal Disease Network and as a clinical researcher for patients with lysosomal diseases. Dr. Jarnes’s research includes projects in the following areas: natural history of gangliosidosis diseases, such as Tay-Sachs disease, Sandhoff disease, and GM1-gangliosidosis, using a substrate reducing therapy protocol for treatment of childhood gangliosidosis diseases, classifying and managing infusion reactions to intravenous enzyme replacement therapies for lysosomal diseases, and pharmacokinetics and pharmacodynamics of ERT and of small molecule therapies.

Research Summary/Interests

  • Longitudinal study of the gangliosidosis diseases and development of new treatment therapies.
  • Pharmacogenetics, pharmacodynamics, and pharmacokinetics of enzyme replacement therapies and small molecule therapies for lysosomal diseases and phenylketonuria (PKU).
  • Combination therapies for lysosomal diseases, including Tay-Sachs disease, Gaucher disease, and MPS diseases.
  • Optimizing management of acute, delayed, and biphasic infusion reactions to intravenous enzyme replacement therapy for lysosomal diseases.
  • Pharmaceutical care impact on clinical outcomes in lysosomal diseases and phenylketonuria (PKU).
  • Lysosomotropic agents and their impact on lysosomal diseases.